Hemochromatosis Pipeline Analysis 2018 (Q1) - ResearchAndMarkets.com

DUBLIN--()--The "Hemochromatosis Pipeline Analysis 2018 (Q1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

Hemochromatosis Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Iron overload means presence of excessive iron in the body. This excessive iron is stored in tissues and organs such as liver, heart etc causing damage to them. Hemochromatosis may be hereditary or acquired due to multiple blood transfusions or intake of excessive iron supplements.

The report provides Hemochromatosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Companies Mentioned

  • La Jolla Pharmaceutical Company
  • Genzyme Corporation
  • DisperSol Technologies LLC
  • Vifor Pharma Management Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Silence Therapeutics
  • Protagonist Therapeutics, Inc.
  • Alnylam Pharmaceuticals
  • Shire Plc
  • Side

Key Topics Covered:

1. Introduction

2. Disease Overview

3. Executive Summary

4. Market Dynamics

5. Pipeline Analysis/Outlook

6. Company profiling

For more information about this report visit https://www.researchandmarkets.com/research/zzkfdc/hemochromatosis?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Hematological Drugs